In cancer models, warfarin inhibits AXL receptor tyrosine kinase-dependent tumorigenesis and enhances antitumor immune responses at doses not reaching anticoagulation levels. This study investigates the association between warfarin use and cancer incidence in a large, unselected population-based cohort.
W arfarin sodium is the most used anticoagulant worldwide and is prescribed to 5% to 10% of the adult population in Western countries 1 for a range of indications, including atrial fibrillation, prosthetic heart valves, and venous thromboembolism. 2, 3 The antitumor potential of warfarin is demonstrated in different experimental cancer model systems. [4] [5] [6] [7] Previous epidemiological studies differ regarding the association between warfarin and cancer, with one suggesting a specific association with urogenital cancers 8 and
another indicating no association with cancer incidence. 9 A clearly defined molecular mechanism of how vitamin K antagonism affects cancer development and a populationbased cohort study are needed to resolve this controversy. Vitamin K in humans serves as a cofactor for gammaglutamyl carboxylase that converts glutamate to γ-carboxyglutamate in substrate N-terminal domains of vitamin K-dependent proteins. This conversion allows vitamin K-dependent proteins to bind calcium and membrane phosphatidylserine moieties with high affinity. 10 The reduced (hydroquinone) active cofactor form of vitamin K is maintained through the action of 2 vitamin K oxidoreductases (VKORC1 and VKORC1L1), which are both potently inhibited by warfarin. 11 Treatment with warfarin depletes vitamin K pools, leading to reduced gammaglutamyl carboxylase activity and noncarboxylated γ-carboxyglutamate domains of vitamin K-dependent proteins. 12 These proteins are comparatively rare in the human genome (numbering ≤14), comprising mainly proteins involved in blood clotting and bone homeostasis. 13 A notable exception is GAS6
(growth arrest-specific 6), the ligand of the AXL receptor tyrosine kinase family associated with immune regulation and cancer. 14 Warfarin treatment inhibits AXL receptor signaling, blocking malignant traits of aggressive carcinoma cells and enhancing antitumor natural killer cell activity at doses that do not affect coagulation. 4, 6 Importantly, noncarboxylated GAS6 retains full AXL binding affinity but is unable to induce receptor activation, thus converting the ligand into a selective AXL antagonist. 10 New oral anticoagulants that target different factors in the coagulation cascade and prevent the need for repeated blood monitoring are gaining favor. Hence, it is important to more clearly determine the cancer-protective potential of warfarin to better inform the decisions on appropriate anticoagulation regimens.
We conducted a population-based study to examine the association between warfarin use and cancer incidence in a large cohort of the Norwegian population.
Methods

Data Sources and Study Design
We conducted a nationwide cohort study using the Norwegian National Registry, a national database that contains information on every person who is currently or has in the past been a resident of Norway. Norway has comprehensive, population-based national health registries with broad coverage that are supported by a universal health care system. A unique identification number assigned to each citizen and permanent resident enables the retrieval of coupled information for different health conditions with a high level of accuracy and completeness. The 11-digit personal identification number includes an individual's date of birth and sex, 15 
Warfarin Exposure Assessment
In Norway, warfarin is only available by prescription. To define regular prediagnostic users, we divided the study cohort into 2 groups-warfarin users and nonusers. According to the hypothesized molecular mechanism, a minimal warfarin exposure period along with a minimal interval between exposure and cancer diagnosis was assumed to be required for warfarin to affect cancer development. The warfarin users group comprised persons who received a warfarin prescription at least 2 years before any cancer diagnosis and with an interval between first and last prescription of at least 6 months. For warfarin users without a cancer diagnosis, the interval between first and last prescription had to be at least 6 months. All other person-years in the cohort were classified as nonusers. The duration of warfarin use was calculated according to the time interval between the first and last prescription of warfarin, with the assumption that the use was continuous between these two dates.
Indication for warfarin use was drawn from the NorPD based on the refund code registered on the prescriptions. For prescriptions dated before March 3, 2008, the coding system did not specify the indication for the warfarin use but used larger groups of diagnosis. After March 3, 2008, patients on warfarin for atrial fibrillation or atrial flutter (AF) were identified by 2 different systems: the ICD-10-CM (code I48) for prescriptions made by hospital physicians and the ICPC (code K78) for prescriptions made by general practitioners. First warfarin prescriptions after March 3, 2008, were used for the AF subgroup analysis; warfarin user criteria were otherwise identical. Warfarin users contributed person-time in the nonusers group until the warfarin user criteria were fulfilled.
Statistical Analysis
Descriptive analyses are given as frequencies and proportions and means with SDs. The study cohort was followed from inclusion to the date of cancer diagnosis, date of death, or end of follow-up (December 31, 2012), whichever occurred first. The primary cancer diagnosis for each person was used for the calculations. We calculated the person-years of observation for each group to account for differences in follow-up time between the groups. To examine the cancer risk for warfarin users compared with nonusers, we calculated the incidence rate ratios (IRRs), adjusting for sex and age (2-year age groups), using the Mantel-Haenszel test. A 95% CI was applied to determine statistical significance. If warfarin treatment started after January 1, 2006, each person contributed person-time to the nonusers group until the person fulfilled the criteria of a warfarin user to avoid immortal-time bias. Site-specific results are presented if the number of cancer incidences in the user group was at least 10 cases. Competing risk regression (method of Fine and Gray
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) was conducted with death as a competing event.
To address the increased risk of cancer after venous thromboembolism and pulmonary embolism, we conducted a sensitivity analysis among the AF subgroup, who were patients prescribed warfarin to prevent thromboembolic events after AF. The IRRs were analyzed for all cancer sites and sitespecific cancers of the AF subgroup and compared with those of the nonusers group.
A separate sensitivity analysis addressed the influence of different time intervals between warfarin prescription and cancer diagnosis in the user definition. All the statistical calculations were performed using Stata/IC, version 13.1 and Stata/ IC, version 14 (StataCorp LLC). Table 1 .
Results
Characteristics of the Cohort
Warfarin Use and Cancer Incidence
In the warfarin users group, 8754 persons (9.4%) received a diagnosis of cancer in 430 266 person-years. In the nonusers group, 123 933 persons (10.6%) received a diagnosis of cancer in 7 577 952 person-years. As expected, the most prevalent cancer sites were prostate, lung, colon, and breast, representing a total of 65 747 persons (49.6%). We observed a significantly lower IRR for all cancer sites in the warfarin users group compared with the nonusers group (adjusted IRR, 0.84; 95% CI, 0.82-0.86) (Table 2;eT able1intheSupplement). A significantly lower IRR in 3 of the 4 most prevalent cancer sites was found in the warfarin users group compared with that in the nonusers group: prostate (IRR, 0.69; 95% CI, 0.65-0.72), lung (IRR, 0.80; 95% CI, 0.75-0.86), and female breast cancer (IRR, 0.90; 95% CI, 0.82-1.00). For lung cancer, subtype analysis revealed a lower IRR for non-small-cell lung carcinoma (IRR, 0.80; 95% CI, 0.74-0.87) and small-cell lung carcinoma (IRR, 0.71; 95% CI, 0.59-0.86) in the warfarin users group compared with the nonusers group (Table 2) .
Sensitivity analyses on all cancer sites' risk stratified by age, sex, and duration of warfarin use are shown in eTable 2 in the Supplement. We detected in the warfarin users group a lower IRR with the shortest and longest warfarin exposures as well as a lower IRR for men than women. No difference in cancer risk was detected when the minimal time interval between warfarin treatment and cancer diagnosis was less than 2 years. Competing risk analysis with death as a competing event confirmed the results despite more deaths occurring in the warfarin users group. Our large population-based study with a subgroup analysis of patients with arrhythmia reveals a remarkable association between warfarin use and lower cancer incidence across a broad range of malignant neoplasms. The well-known challenges of warfarin dosing that necessitate regular monitoring have fueled a transition to new oral anticoagulants. 19 An unintended consequence of this switch to new oral anticoagulants may be an increased incidence of cancer, which is an important consideration for public health. Thromboembolic disease is associated with an elevated cancer risk, especially the first year after the diagnosis, and this is an important potential confounder. 20, 21 Patients with AF routinely receive warfarin treatment to prevent embolic strokes. 22 Hence, this subgroup lacks the occult preexisting malignant neoplasm characteristic associated with patients with thromboembolic events. A large number of patients with AF were identified in the cohort, and the association between warfarin use and lower cancer incidence in this subgroup was stronger compared with that in groups in the main analysis. This finding supports the hypothesis that warfarin may exert considerable cancer protection against major carcinoma types. By inhibiting GAS6-AXL signaling, warfarin blocks tumorigenesis (independent of anticoagulation) in murine models.
4,6,23 Importantly, AXL signaling suppresses antitumor immunity. 6,24 Hence, the observed association between warfarin use and lower cancer incidence is likely due in part to an enhanced antitumor immune surveillance of early can- cer. Congruently, warfarin is associated with immune activation, and autoimmune disorders are reported as an adverse effect.
6,25,26
Results from this study show that warfarin therapy is associated with a lower incidence for many but not all cancer sites. Clinical practice in Norway ensures that suspected cancer is biopsied and biopsied also for persons receiving warfarin treatment. Nevertheless, the incidence of superficial cancer (eg, skin) is just as common in warfarin users as in nonusers, whereas several screening-detected cancers (eg, prostate, breast) have a lower incidence. On the other hand, we observed no difference in colorectal cancer, which is suspected to be more apparent when a patient receives anticoagulation therapy (such as in colorectal neoplasia with hematochezia). Interestingly, these observations correspond with reported AXL expression, which is prevalent in lung and breast cancers, for example, but lower in nonmelanoma skin cancers and lymphomas. 27 To our knowledge, this observational cohort study is the first to use large, nationwide cancer and prescription registries to examine the association between warfarin therapy and cancer incidence. The coupled Norwegian health registries provided a reliable basis for our investigation and enabled the formation of a population-level cohort with numerous diverse cancer cases and long-term follow-up. Selection bias is unlikely as the cohort was extracted from a national registry that includes all residents within the selected age group. Cancer cases were identified using the CRN with 99% coverage. 16 The risk of recall bias for warfarin use is eliminated by the NorPD, which has had nearly complete coverage since 2004.
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Prescription data may overestimate drug exposure as not all prescriptions were filled. Our warfarin user definition minimizes this bias. Short-term or unfilled prescriptions were excluded to avoid compliance issues. Furthermore, patients' international normalized ratio levels were closely monitored by health professionals to adjust warfarin dosage and optimize anticoagulation. This monitoring contributes to the detection of symptoms of undiagnosed cancer. Focusing on cancer incidence 2 years after treatment highlights the influence of warfarin on early neoplasia. Most patients (71 688 [77.1%]) continued warfarin therapy for more than 2 years, with a mean Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphatic leukemia; IRR, incidence rate ratio (adjusted for sex and age); NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer. (SD) duration of 4.8 (2.8) years. Patients with transient risk factors generally did not receive warfarin treatment beyond 3 to 6 months, although this decision remains at the discretion of the treating physician. This discontinuation may in part account for the lower IRR in the small fraction of patients who received warfarin therapy for 6 to 24 months. Differences in cancer risk between patients who received short-term and those who received long-term warfarin treatment could influence the observed IRR differences in treatment duration. Overall, most patients treated with warfarin have poorer health and higher cancer risk compared with a healthy population. Many of the risk factors for cancer are the same risk factors for AF and thromboembolic disease, such as alcohol use, obesity, and smoking.
20,28
Another source of potential bias is that warfarin treatment criteria may exclude patients with complicating comorbidities or other tolerance issues. No alternative anticoagulation treatments were available for comparison during the study period. Patients with severe comorbidities may be less likely to participate in established cancer screening programs (eg, mammography, Papanicolaou test).
Limitations
This study has several limitations. First, an important but quantitatively modest limitation is that the NorPD lacks information on medications dispensed in hospitals and nursing homes, and this missing data could have led to the systematic misclassification of some individuals as nonusers. In addition, we did not have access to prescription data before 2004. Thus, individuals may have used warfarin longer than the time registered, or warfarin therapy may have been discontinued prior to 2004 and users were misclassified as nonusers. These misclassifications are expected to decrease the observed warfarinassociated cancer protection. Interruptions in treatment between first and last prescription among warfarin users may not be detected, leading to the misclassification of person-years without treatment in the warfarin users group and potentially increasing the observed association between warfarin use and lower cancer incidence.
Second, information was missing on comedications used by patients that may affect cancer development, such as statins, β-blockers, and angiotensin-converting enzyme inhibitors. 8, 29, 30 However, a case-control study identified a protective association of warfarin with prostate cancer (IRR, 0.67-0.80) depending on the length of treatment and after controlling for potential confounders by other drugs. Third, there was a potential bias due to the lack of information on cancer diagnoses prior to the study start. Thus, some registered cancer occurrences might have been recurrences. Fourth, information on lifestyle choices (eg, diet, weight management, or smoking) was unavailable in the registries and could not be addressed. Alcoholism and liver disease are contraindications for warfarin treatment and risk factors for cancer development. We observed a significantly lowered IRR for alcohol-related cancers, such as head and neck cancer and liver cancer.
2 Some of this observed association could be explained by a lack of these risk factors in the warfarin users group.
Conclusions
Conflicting conclusions on the association between warfarin anticoagulation therapy and cancer risk have been reported (eg, Tagalakis et al 31 )
. A prospective randomized clinical trial comparing 6 months with 6 weeks of warfarin therapy following venous thromboembolism reported a significant reduction in incidence among those in the 6-month group after 8 years of follow-up. 32 However, a separate study found no significant reduction in cancer after extending warfarin treatment to 1 year in patients with initial occurrence of venous thromboembolism. 33 A case-control study found no significant difference in bladder cancer risk
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; similarly, a recent study did not observe a decreased risk of prostate cancer among warfarin users.
9 Notably, these studies included any warfarin exposure, including short-term treatment and treatment prior to cancer diagnosis, leading to a higher number of warfarin users (13% to 16%) than observed in our study cohort and than expected in a general population (eg, 3% to 9%). 1 In contrast,
we applied a stricter definition of warfarin use, with a 2-year minimum time interval between start of warfarin treatment and cancer diagnosis, to test the hypothesis that warfarin may affect earlier-stage neoplasia. Cancer development is a protracted process spanning many years. Hence, enforcing a strict definition of warfarin use, with a minimum time interval between start of warfarin treatment and cancer diagnosis, is necessary for warfarin treatment to plausibly influence cancer incidence. Our results document a lower incidence of cancer associated with warfarin in a population-level study. We observed a lower relative risk in a large cohort comprising many different cancer types, reinforced by a subgroup analysis of patients with AF who were receiving warfarin treatment to prevent thromboembolic events. Our data indicate that warfarin provides a possible cancer protection, a finding that may have important implications for choosing medications for patients who need anticoagulation. Further studies are warranted to fully elucidate the mechanisms underpinning these observations. 
